All In Biotech

Drug Trial Radar · NCT07341152

A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants

A Study to Assess the Pharmacokinetics and Relative Bioavailability of Crystalline LTG-001 Immediate Release Tablets Compared to LTG-001 SDD Formulation in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Oct 6, 2025

Primary completion

Nov 17, 2025

Study completion Nov 17, 2025

Sponsor

Lead sponsor
Latigo BiotherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, part-randomized, crossover study in 14 healthy participants to assess the PK and safety profile of an SDD formulation of LTG-001 and two crystalline LTG-001 Instant Release tablet formulations, one of which will also be assessed at a differing dose level.

Conditions

  • Pain Management

Interventions

  • LTG-001 SDDDrug

    LTG-001

  • LTG-001 Formulation A Prototype 1Drug

    LTG-001

  • LTG-001 Formulation B Prototype 2Drug

    LTG-001

  • LTG-001 Formulation B prototype 2Drug

    LTG-001 High Dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the relative bioavailability of two different LTG-001 crystalline formulations (test) compared to the LTG-001 SDD formulation (reference) in the fasted state.Time frame: From enrollment to Period 4, Day 3 Discharge
  2. Determine the relative bioavailability of two different LTG-001 crystalline formulations (test) compared to the LTG-001 SDD formulation (reference) in the fasted stateTime frame: from enrollment to Period 4, Day 3 discharge
  3. Determine the relative bioavailability of two different LTG-001 crystalline formulations (test) compared to the LTG-001 SDD formulation (reference) in the fasted state.Time frame: from enrollment to Period 4, Day 3 discharge
  4. To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted state.Time frame: From Enrollment to Period 4, Day 3 discharge
  5. To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted stateTime frame: From enrollment to period 4, Day 3 Discharge
  6. To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted state.Time frame: enrollment to Period 4, Day 3 discharge
  7. To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted state.Time frame: from enrollment to Period 4, Day 3 discharge
  8. To characterize the PK of LTG-001 and metabolites LTGO-4247 and LTGO-4449, following single administrations of up to two dose levels of two different LTG-001 IR tablet formulations in the fasted state.Time frame: from enrollment to Period 4, Day 3 discharge

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences - Miami, Inc

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.